Opthea Appoints Chief Medical Officer and Chief Financial Officer as Company Prepares for Phase 3 Topline Data Readouts in 2025
Opthea Limited - American Depositary Shares (OPT)
Company Research
Source: GlobeNewswire
Parisa Zamiri, MD, PhD, and Tom Reilly respectively appointed CMO and CFO Anand Sundaram appointed Vice President Marketing MELBOURNE, Australia and PRINCETON, N.J., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced three senior hires as the Company continues to prepare for the sozinibercept Phase 3 topline data readouts of COAST anticipated in early Q2 calendar year 2025 and ShORe in mid calendar year 2025. “Opthea is at an inflection point with the anticipated sozinibercept Phase 3 topline data readouts in 2025 and subsequent US and other regulatory submissions around the world,” said Frederic Guerard, PharmD, Chief Executive Officer, Opthea. “The appointments of Dr. Parisa Zamiri as Chief Medical Officer, Tom Reilly as Chief Financial
Show less
Read more
Impact Snapshot
Event Time:
OPT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OPT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OPT alerts
High impacting Opthea Limited - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
OPT
News
- Opthea Appoints Kathy Connell to Board of Directors [Yahoo! Finance]Yahoo! Finance
- Opthea Appoints Kathy Connell to Board of DirectorsGlobeNewswire
- Opthea’s Wet AMD Program Featured at Ophthalmology EventsGlobeNewswire
- Age-Related Macular Degeneration (AMD) Drugs Market Research 2024: Lucentis, Eylea, Eylea HD, Vabysmo, Syfovre, Ranibizumab, Aflibercept, Faricimab, Biologic, Biosimilar - Global Forecast to 2029 [Yahoo! Finance]Yahoo! Finance
- Opthea to Participate in November Investor ConferencesGlobeNewswire
OPT
Sec Filings
- 11/19/24 - Form 6-K
- 11/15/24 - Form 6-K
- 11/14/24 - Form SC
- OPT's page on the SEC website